Protocol 15-0020: targeted reduction of antibiotics using procalcitonin in a multi-center, randomized, blinded, placebo-controlled non-inferiority study of azithromycin treatment in outpatient…

Ended Awarded Last action

Contract number
HHSN27200014
Awardee
Awarding agency
Obligated
$1,337,269

Award facts

Opportunity
Contract value 71% obligated
  • $1,337,268.68 Current, with exercised options
  • $1,896,784.68 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
Pricing
Cost No Fee
Place of performance
Durham, NC 27705, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00013 · To DE-obligate remaining funds and administratively close the task order. -$552,154
Supplemental Agreement for work within scope P00012 -$14,512
Supplemental Agreement for work within scope P00011 $0
Supplemental Agreement for work within scope P00010 $0
Supplemental Agreement for work within scope P00009 $135,755
Supplemental Agreement for work within scope P00008 $341,103
Exercise an Option P00007 $340,114
Other Administrative Action 6 $0
Exercise an Option 5 $334,188
Funding Only Action 4 $46,674
Other Administrative Action 3 $0
Exercise an Option 2 $619,820
Other Administrative Action 1 $0
Original award $86,281
Show all 14

About this award

Written by GovTribe AI ·

This federal contract award is for a task order under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery/indefinite quantity (IDIQ) contract. The task order, valued at $1,896,784.68, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Duke University as the prime contractor.

The task order is for a clinical research study titled "PROTOCOL 15-0020: TARGETED REDUCTION OF ANTIBIOTICS USING PROCALCITONIN IN A MULTI-CENTER, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED NON-INFERIORITY STUDY OF AZITHROMYCIN TREATMENT IN OUTPATIENT ADULTS WITH SUSPECT LOWER RESPIRATORY TRACT INFECTION (LRTI) AND A PROCALCITONIN LEVEL OF 0.1 NG/ML." The study aims to evaluate the use of procalcitonin in reducing antibiotic use for outpatient adults with suspected lower respiratory tract infections. The contract has no set-aside designation and runs through November 15, 2021.

Description

As the agency reported it.

Protocol 15-0020: targeted reduction of antibiotics using procalcitonin in a multi-center, randomized, blinded, placebo-controlled non-inferiority study of azithromycin treatment in outpatient adults with suspect lower respiratory tract infection (lrti)and a procalcitonin level of≤0.1 NG/ML.

Quick answers

Who was awarded contract HHSN27200014?

HHSN27200014 was awarded to Duke University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 14, 2016.

How much is contract HHSN27200014 worth?

The government has obligated $1,337,269 on HHSN27200014. Its potential value, with all options, is $1,896,785.

Is contract HHSN27200014 an order under another contract?

Yes. HHSN27200014 is a delivery order under HHSN272201300017I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).

Was contract HHSN27200014 competed?

The extent of competition for HHSN27200014 was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login